Biological markers in CSF and blood for axonal degeneration in multiple sclerosis

[1]  Jean-Paul Noben,et al.  Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients , 2004, Proteomics.

[2]  P. Vermersch,et al.  New antigenic candidates in multiple sclerosis: Identification by serological proteome analysis , 2004, Proteomics.

[3]  Roland Martin,et al.  Development of biomarkers in multiple sclerosis. , 2004, Brain : a journal of neurology.

[4]  P. Scheltens,et al.  Biomarkers for Alzheimer’s disease. Which way to go? , 2004, Neurobiology of Aging.

[5]  A. Saiz,et al.  Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis , 2004, Neuroscience Letters.

[6]  S. Hunsucker,et al.  Proteomic analysis of multiple sclerosis cerebrospinal fluid , 2004, Multiple sclerosis.

[7]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[8]  J. Archelos,et al.  Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG , 2004, Journal of Neurology.

[9]  L. Wahlund,et al.  Diagnostic use of cerebral and extracerebral oxysterols , 2004, Clinical chemistry and laboratory medicine.

[10]  L. Rosengren,et al.  Cerebrospinal fluid markers in MS patients and their healthy siblings , 2004, Acta neurologica Scandinavica.

[11]  H. Budka,et al.  Increased 14-3-3 immunoreactivity in glial elements in patients with multiple sclerosis , 2004, Acta Neuropathologica.

[12]  L. Rosengren,et al.  Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2003, Neurology.

[13]  M. Vitek,et al.  APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory Response* , 2003, Journal of Biological Chemistry.

[14]  N. Stefano,et al.  Imaging neuronal and axonal degeneration in multiple sclerosis , 2003, Neurological Sciences.

[15]  N. Norgren,et al.  Elevated neurofilament levels in neurological diseases , 2003, Brain Research.

[16]  D. Berg,et al.  14-3-3 proteins in the nervous system , 2003, Nature Reviews Neuroscience.

[17]  C. Caltagirone,et al.  Apolipoprotein E genotype does not influence the progression of multiple sclerosis , 2003, Journal of Neurology.

[18]  C. Polman,et al.  Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients , 2003, Neuroscience Letters.

[19]  J. Satoh,et al.  Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis , 2003, Journal of the Neurological Sciences.

[20]  S. Kikuchi,et al.  Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis , 2003, Multiple sclerosis.

[21]  Lars Ulrik Gerdes,et al.  The Common Polymorphism of Apolipoprotein E: Geographical Aspects and New Pathophysiological Relations , 2003, Clinical chemistry and laboratory medicine.

[22]  M. Cynader,et al.  Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. , 2003, The American journal of pathology.

[23]  Wickliffe C Abraham,et al.  Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory , 2003, Progress in Neurobiology.

[24]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[25]  I. Björkhem,et al.  Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers Published, JLR Papers in Press, February 1, 2003. DOI 10.1194/jlr.M200434-JLR200 , 2003, Journal of Lipid Research.

[26]  K. Nave,et al.  Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination , 2003, Nature Genetics.

[27]  B. Trapp,et al.  Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease , 2003, Journal of the Neurological Sciences.

[28]  Y. Ron,et al.  Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. , 2003, Brain : a journal of neurology.

[29]  N. Roberts,et al.  C erebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years , 2003, Multiple sclerosis.

[30]  R. Pearlstein,et al.  Protective effect of apolipoprotein E-mimetic peptides on N-methyl-d-aspartate excitotoxicity in primary rat neuronal–glial cell cultures , 2003, Neuroscience.

[31]  F. Barkhof,et al.  Multiple sclerosis , 2003, Neurology.

[32]  J. Hillert,et al.  Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis , 2002, Neuroscience Letters.

[33]  Wolfgang Brück,et al.  Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.

[34]  Carlos G. Dotti,et al.  Breaking the neuronal sphere: regulation of the actin cytoskeleton in neuritogenesis , 2002, Nature Reviews Neuroscience.

[35]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[36]  P. Sørensen,et al.  Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) , 2002, Multiple sclerosis.

[37]  E. Silber,et al.  Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit , 2002, Neurology.

[38]  P. Vermersch,et al.  14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis , 2002, Journal of Neurology.

[39]  E. Jauch,et al.  Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. , 2002, Annals of emergency medicine.

[40]  J. Haines,et al.  Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis. , 2002, American journal of human genetics.

[41]  M. Sharief,et al.  Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability , 2002, Journal of Neuroimmunology.

[42]  M. Seipelt,et al.  Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke , 2002, European Neurology.

[43]  C. Enzinger,et al.  Apolipoprotein E ε4 is associated with rapid progression of multiple sclerosis , 2001, Neurology.

[44]  H. Neumann,et al.  Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. , 2001, The American journal of pathology.

[45]  R. Sánchez-Valle,et al.  14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis , 2001, Neurology.

[46]  H. Reiber,et al.  Dynamics of brain-derived proteins in cerebrospinal fluid. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[47]  F Barkhof,et al.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. , 2001, Brain : a journal of neurology.

[48]  A. Blokland,et al.  Apolipoprotein E Protects against Neuropathology Induced by a High-Fat Diet and Maintains the Integrity of the Blood-Brain Barrier during Aging , 2001, Laboratory Investigation.

[49]  A. Compston,et al.  Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.

[50]  H. Lassmann,et al.  Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2001, Brain : a journal of neurology.

[51]  H. Reiber,et al.  Tau protein in cerebrospinal fluid (CSF): a blood–CSF barrier related evaluation in patients with various neurological diseases , 2001, Neuroscience Letters.

[52]  L. Roccatagliata,et al.  Demyelination and axonal damage in a non-human primate model of multiple sclerosis , 2001, Journal of the Neurological Sciences.

[53]  D. Michaelson,et al.  APOE genotype is a major predictor of long-term progression of disability in MS , 2001, Neurology.

[54]  S. Sorbi,et al.  Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis , 2000, Neuroscience Letters.

[55]  R. Rudick,et al.  Neurological disability correlates with spinal cord axonal loss and reduced N‐acetyl aspartate in chronic multiple sclerosis patients , 2000, Annals of neurology.

[56]  H. Lassmann,et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.

[57]  S Ropele,et al.  Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[58]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[59]  W. Brück,et al.  Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.

[60]  L. Bretillon,et al.  Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. , 2000, Journal of lipid research.

[61]  M. Michalopoulou,et al.  Increased Cerebrospinal Fluid Tau Protein in Multiple Sclerosis , 2000, European Neurology.

[62]  C. Kaether,et al.  Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. , 2000, Molecular biology of the cell.

[63]  R. Strange,et al.  Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis , 2000, Multiple sclerosis.

[64]  M. Palkovits,et al.  Axonal changes in chronic demyelinated cervical spinal cord plaques. , 2000, Brain : a journal of neurology.

[65]  F. Jessen,et al.  Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. , 2000, Journal of lipid research.

[66]  V. Stevenson,et al.  Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis , 1999, Multiple sclerosis.

[67]  J M Guileyardo,et al.  cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Mahley,et al.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.

[69]  J. Lanchbury,et al.  Meta‐analysis of genome searches , 1999, Annals of human genetics.

[70]  R. Rudick,et al.  Quantification of Axonal Damage in Traumatic Brain Injury , 1999, Journal of neurochemistry.

[71]  S. Teukolsky,et al.  Black Holes , 1998, gr-qc/9808035.

[72]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[73]  J. Delattre,et al.  Apolipoprotein E and multiple sclerosis: A biochemical and genetic investigation , 1998, Journal of the Neurological Sciences.

[74]  O. Hommes,et al.  Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis , 1998, Multiple sclerosis.

[75]  D. Terwel,et al.  Possible Link between Lipid Metabolism and Cerebral Amyloid Angiopathy in Alzheimer’s Disease: A Role for High-Density Lipoproteins? , 1998, Pathophysiology of Haemostasis and Thrombosis.

[76]  A. Roses,et al.  Apolipoprotein E and the CNS Response to Injury , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  B. Ghetti,et al.  Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies , 1998, Brain pathology.

[78]  L. Rosengren,et al.  Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[79]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[80]  H. Akiyama,et al.  Glial Tau Pathology in Neurodegenerative Diseases: Their Nature and Comparison with Neuronal Tangles , 1998, Neurobiology of Aging.

[81]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[82]  E. Fuchs,et al.  A structural scaffolding of intermediate filaments in health and disease. , 1998, Science.

[83]  V. Perry,et al.  Axonal damage in acute multiple sclerosis lesions. , 1997, Brain : a journal of neurology.

[84]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[85]  J. Haines,et al.  A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex , 1996, Nature Genetics.

[86]  M. Beal,et al.  Increased 3-nitrotyrosine in brains of Apo E-deficient mice , 1996, Brain Research.

[87]  G. Kreutzberg,et al.  Amyloid precursor protein (APP) expression in multiple sclerosis lesions , 1995, Glia.

[88]  G. Borm,et al.  Cerebrospinal neuron‐specific enolase, S‐100 and myelin basic protein in neurological disorders , 1995, Acta neurologica Scandinavica.

[89]  A. Monji,et al.  Effect of dietary vitamin E on lipofuscin accumulation with age in the rat brain , 1994, Brain Research.

[90]  P. Wong,et al.  Neurofilaments are obligate heteropolymers in vivo , 1993, The Journal of cell biology.

[91]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[92]  A. Haase,et al.  Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes , 1991, Journal of virology.

[93]  M. Lazdunski,et al.  Increase of sodium channels in demyelinated lesions of multiple sclerosis , 1991, Brain Research.

[94]  N. Rifai,et al.  Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. , 1987, Clinical chemistry.

[95]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[96]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[97]  G. Davies-Jones,et al.  Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system. , 1983, Journal of neurology, neurosurgery, and psychiatry.

[98]  L. S. King,et al.  OBSERVATIONS ON THE HISTOPATHOLOGY OF THE CEREBRAL LESIONS IN DISSEMINATED SCLEROSIS , 1936 .

[99]  Morris H. Baslow,et al.  Brain N-acetylaspartate as a molecular water pump and its role in the etiology of canavan disease , 2007, Journal of Molecular Neuroscience.

[100]  T. Lehtimäki,et al.  Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease , 2004, Human Genetics.

[101]  G. Johnson,et al.  Tau, where are we now? , 2002, Journal of Alzheimer's disease : JAD.

[102]  P M Matthews,et al.  Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.

[103]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[104]  N. Rifai,et al.  Cerebrospinal fluid and plasma apolipoproteins in patients with multiple sclerosis. , 1988, Annals of clinical and laboratory science.

[105]  V. Zannis.  [49] Genetic polymorphism in human apolipoprotein E , 1986 .